

Manu V Chakravarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4166908/publications.pdf>

Version: 2024-02-01

55
papers

4,388
citations

230014

27
h-index

223390

49
g-index

60
all docs

60
docs citations

60
times ranked

6661
citing authors

#	ARTICLE	IF	CITATIONS
1	848 A NOVEL, PRECISION-ENGINEERED AMINO ACID COMPOSITION, AXA1665, IS SAFE, WELL-TOLERATED AND IMPROVES NEUROCOGNITION AND PHYSICAL FUNCTION IN CHILD-PUGH A AND B SUBJECTS. <i>Gastroenterology</i> , 2021, 160, S-796.	0.6	0
2	A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. <i>Scientific Reports</i> , 2021, 11, 11861.	1.6	10
3	752-P: LIVRQNaC (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D. <i>Diabetes</i> , 2021, 70, .	0.3	0
4	Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2399-2409.	0.2	9
5	Nutrition and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 63-94.	1.0	44
6	Safety, Tolerability, and Physiological Effects of AXA1665, a Novel Composition of Amino Acids, in Subjects With Child-Pugh A and B Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00222.	1.3	12
7	Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D). <i>Journal of Hepatology</i> , 2020, 73, S123.	1.8	2
8	Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 592373.	1.5	42
9	Endogenous Metabolic Modulators: Emerging Therapeutic Potential of Amino Acids. <i>IScience</i> , 2020, 23, 101628.	1.9	13
10	The metabolic basis of nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00112.	1.0	64
11	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 575843.	1.5	43
12	S1178 Utility and Interpretation of the Quantitative MRI Metrics PDFF and cT1 as Biomarkers for Non-Alcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2020, 115, S589-S590.	0.2	0
13	A Novel Amino Acid Composition Ameliorates Short-Term Muscle Disuse Atrophy in Healthy Young Men. <i>Frontiers in Nutrition</i> , 2019, 6, 105.	1.6	27
14	LBP-31-AXA1665, a novel composition of amino acids restores the dysregulated amino acid profile, lowers ammonia, and improves body composition and function in Child-Pugh class A and B subjects. <i>Journal of Hepatology</i> , 2019, 70, e156.	1.8	0
15	Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Olanacatib in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 861-870.	0.8	0
16	Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 441-451.	1.1	12
17	Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetes. <i>BMC Obesity</i> , 2017, 4, 10.	3.1	14
18	Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-0666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection. <i>Clinical and Translational Science</i> , 2017, 10, 404-411.	1.5	11

#	ARTICLE	IF	CITATIONS
19	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. <i>Cell Metabolism</i> , 2017, 26, 394-406.e6.	7.2	265
20	Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. <i>Gastroenterology</i> , 2017, 153, 621-625.e7.	0.6	24
21	Effects of 13-Hour Hyperglucagonemia on Energy Expenditure and Hepatic Glucose Production in Humans. <i>Diabetes</i> , 2017, 66, 36-44.	0.3	23
22	Decreased complexity of glucose dynamics preceding the onset of diabetes in mice and rats. <i>PLoS ONE</i> , 2017, 12, e0182810.	1.1	15
23	Increased Bile Acid Synthesis and Impaired Bile Acid Transport in Human Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1935-1944.	1.8	102
24	An LC-MRM method for measuring intestinal triglyceride assembly using an oral stable isotope-labeled fat challenge. <i>Bioanalysis</i> , 2016, 8, 1265-1277.	0.6	3
25	Abstract 46: Bile Acid Synthesis and 12-Hydroxylation are Increased, and Bile Acid Transport is Impaired in Human Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	1
26	Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. <i>Diabetes</i> , 2015, 64, 3377-3385.	0.3	66
27	Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1520-1526.	2.8	14
28	Could the mechanisms of bariatric surgery hold the key for novel therapies?: report from a Pennington Scientific Symposium. <i>Obesity Reviews</i> , 2011, 12, 984-994.	3.1	41
29	De Novo Lipogenesis Maintains Vascular Homeostasis through Endothelial Nitric-oxide Synthase (eNOS) Palmitoylation*. <i>Journal of Biological Chemistry</i> , 2011, 286, 2933-2945.	1.6	105
30	Macrophage Fatty-acid Synthase Deficiency Decreases Diet-induced Atherosclerosis. <i>Journal of Biological Chemistry</i> , 2010, 285, 23398-23409.	1.6	57
31	Inactivation of hypothalamic FAS protects mice from diet-induced obesity and inflammation. <i>Journal of Lipid Research</i> , 2009, 50, 630-640.	2.0	41
32	Identification of a Physiologically Relevant Endogenous Ligand for PPAR α in Liver. <i>Cell</i> , 2009, 138, 476-488.	13.5	589
33	Identification of a Physiologically Relevant Endogenous Ligand for PPAR α in Liver. , 2009, 138, 476-488.		0
34	Identification of a Physiologically Relevant Endogenous Ligand for PPAR α in Liver. , 2009, 138, 476-488.		0
35	Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long $\text{\textcircled{E}}$ Evans Tokushima Fatty (OLETF) rats. <i>Journal of Physiology</i> , 2008, 586, 4241-4249.	1.3	88
36	Insulin Resistance and Atherosclerosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 603-621.	1.2	82

#	ARTICLE	IF	CITATIONS
37	Decreased Fetal Size Is Associated With β -Cell Hyperfunction in Early Life and Failure With Age. <i>Diabetes</i> , 2008, 57, 2698-2707.	0.3	25
38	Respiratory Uncoupling in Skeletal Muscle Delays Death and Diminishes Age-Related Disease. <i>Cell Metabolism</i> , 2007, 6, 497-505.	7.2	96
39	The ABCs of β -cell dysfunction in type 2 diabetes. <i>Nature Medicine</i> , 2007, 13, 241-242.	15.2	12
40	Brain fatty acid synthase activates PPAR α to maintain energy homeostasis. <i>Journal of Clinical Investigation</i> , 2007, 117, 2539-2552.	3.9	183
41	Physical activity and dietary intervention for chronic diseases: a quick fix after all?. <i>Journal of Applied Physiology</i> , 2006, 100, 1439-1440.	1.2	5
42	Novel hepatic fat activates PPAR α to maintain glucose, lipid, and cholesterol homeostasis. <i>Cell Metabolism</i> , 2005, 1, 309-322.	7.2	462
43	Eating, exercise, and thrifty genotypes: connecting the dots toward an evolutionary understanding of modern chronic diseases. <i>Journal of Applied Physiology</i> , 2004, 96, 3-10.	1.2	371
44	Inactivity and Inaction. <i>JAMA Pediatrics</i> , 2003, 157, 731.	3.6	12
45	Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. <i>Journal of Applied Physiology</i> , 2002, 93, 3-30.	1.2	339
46	p27Kip1: A Key Regulator of Skeletal Muscle Satellite Cell Proliferation. <i>Clinical Orthopaedics and Related Research</i> , 2002, 403, S221-S227.	0.7	9
47	An Obligation for Primary Care Physicians to Prescribe Physical Activity to Sedentary Patients to Reduce the Risk of Chronic Health Conditions. <i>Mayo Clinic Proceedings</i> , 2002, 77, 165-173.	1.4	89
48	An Obligation for Primary Care Physicians to Prescribe Physical Activity to Sedentary Patients to Reduce the Risk of Chronic Health Conditions. <i>Mayo Clinic Proceedings</i> , 2002, 77, 165-173.	1.4	129
49	Exercise and gene expression: physiological regulation of the human genome through physical activity. <i>Journal of Physiology</i> , 2002, 543, 399-411.	1.3	191
50	The Molecular Responses of Skeletal Muscle Satellite Cells to Continuous Expression of IGF-1: Implications for the Rescue of Induced Muscular Atrophy in Aged Rats. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2001, 11, S44-S48.	1.0	37
51	Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. <i>Cellular and Molecular Life Sciences</i> , 2001, 58, 1150-1158.	2.4	76
52	Long-term insulin-like growth factor-I expression in skeletal muscles attenuates the enhanced in vitro proliferation ability of the resident satellite cells in transgenic mice. <i>Mechanisms of Ageing and Development</i> , 2001, 122, 1303-1320.	2.2	26
53	IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. <i>Journal of Applied Physiology</i> , 2000, 89, 1365-1379.	1.2	228
54	Insulin-like Growth Factor-I Extends in Vitro Replicative Life Span of Skeletal Muscle Satellite Cells by Enhancing G1/S Cell Cycle Progression via the Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2000, 275, 35942-35952.	1.6	194

#	ARTICLE	IF	CITATIONS
55	Protein Structure and Chromatographic Behavior: The Separation and Characterization of Four Proteins Using Gel Filtration and Ion-Exchange Chromatography and Gel Electrophoresis. Journal of Chemical Education, 1996, 73, 268.	1.1	9